supported by Grants from the National Natural Science Foundation of China (No. 81070102);Foundation of the Guangdong Provincial Science and Technology (20100309);the Natural Science Foundation of the Guangdong Province (Nos. 10151008004000035, S2011020005911)
Background The co-administration of dexrazoxane (DEX) with each dose of doxoruhicin (Dox) is an efficient strategy to relieve Dox-induced cardiotoxicity, however, the mechanisms underlying the cardioprotective eff...